Mr. Levitt is a Vice President of Pharmakon, having joined in 2017. Mr. Levitt spent the prior 5 years in various positions in the healthcare finance industry, most recently as a Senior Equity Research Associate covering the Medical Device and Life Science sectors at Evercore. Prior to joining Evercore, he was an Associate at Roberts Mitani, a boutique healthcare investment bank where he advised on biotech, pharmaceutical, device and diagnostic M&A transactions, private placements, and venture capital investments. Mr. Levitt previously worked in the medical device industry in R&D and process engineering and conducted clinical research at the Hospital of the University of Pennsylvania. Mr. Levitt earned a B.S.E. in Bioengineering and Engineering Entrepreneurship from the University of Pennsylvania.

Mr. Gruber is a Vice President of Pharmakon, having joined in 2019. Prior to joining Pharmakon, Dr. Gruber served as a Senior Research Associate at Deutsche Bank and JMP Securities covering the Small/Mid‐cap Biotechnology sector. Prior to his career on Wall Street, Dr. Gruber served as a Business Development Analyst at Mount Sinai Innovation Partners, where he vetted novel technologies developed by Mount Sinai faculty for licensing and commercial development. Dr. Gruber also previously served as a consultant for Photonic Pharma, a biotechnology company founded based on technology he helped develop and patented in graduate school. Dr. Gruber was a postdoctoral research associate at the Icahn School of Medicine at Mount Sinai and received his Ph.D. in Biophysics as well as B.S. degrees in Chemistry and Genetics, Cell Biology, and Development from the University of Minnesota.

Mr. Helfaer is a Vice President of Pharmakon, having joined in 2024. Mr. Helfaer spent the prior 11 years in various positions of increasing seniority at Athyrium Capital Management, most recently serving as a Principal, focused on investments in biotechnology and the broader healthcare industry. He has evaluated, originated, and managed investments across the capital structure including debt, equity, royalty-linked and convertible debt of both public and private companies. Prior to that, Mr. Helfaer was an Analyst at Bank of America/Merrill Lynch in the Global Healthcare Group. Mr. Helfaer earned a B.S. in Physics from Yale University.

Mr. Shah is a Vice President of Pharmakon, having joined in 2021. Prior to joining Pharmakon, Mr. Shah spent 5 years at Citi in their healthcare coverage group, most recently as an Investment Banking Associate. While at Citi, Mr. Shah advised on several transactions including M&A transactions, equity and equity‐linked offerings, and debt offerings in the Life Sciences, Services, and LST/Dx space. Mr. Shah earned a B.S. in Finance from Rutgers University.

Mr. Graz is an Associate of Pharmakon, having joined in 2024. Prior to joining Pharmakon, Mr. Graz spent 2 years at MTS Health Partners, a boutique healthcare-focused investment bank, most recently as a Senior Analyst. While at MTS Health Partners, Mr. Graz advised on several transactions, including M&A transactions and equity financings in the Life Sciences and Services space. Mr. Graz earned a B.A. in Neuroscience with a Certificate in Markets and Management Studies from Duke University.

Mr. Kim is the General Counsel and Chief Compliance Officer of Pharmakon. Prior to joining Pharmakon in 2022, Mr. Kim was an Executive Director in the Legal and Compliance Division at Morgan Stanley, as the senior legal coverage officer for leveraged and acquisition finance and debt capital markets. Prior to Morgan Stanley, Mr. Kim was a Senior Associate at Milbank LLP, and a member of their Global Project, Energy and Infrastructure Finance group. Mr. Kim graduated with a J.D. from Harvard Law School and a B.A. in History (Honors) from Yale University.

Mr. Fisher is a Vice President of Pharmakon, having joined in 2020 and is responsible for investor relations and fundraising. Prior to joining Pharmakon, Mr. Fisher was a Director at Garrison Investment Group and was responsible for business development and investor relations. Prior to joining Garrison, Mr. Fisher was an Associate at SAC Capital Advisors where was a member of the marketing & investor relations team and focused on strategic projects, capital raising and servicing existing client relationships. Prior to SAC, Mr. Fisher worked in the Client Services Group at KKR. Previously, Mr. Fisher worked in the Private Wealth Management group Brown Brothers Harriman & Co. Mr. Fisher graduated from Brown University with a B.A. in Economics.

Mr. Caprio is a Vice President and Controller of Pharmakon, having joined in 2009. Prior to joining Pharmakon, Mr. Caprio was a senior auditor in the financial services practice at Deloitte and Touche in New York City from 2006 to 2009 and an auditor at RSM McGladrey, Inc. from 2004‐2006. During the 5 years prior to joining the Investment Manager, Mr. Caprio performed audits on various private equity and hedge fund clients in the financial services and healthcare industries. Mr. Caprio graduated from Quinnipiac University with a B.S. in Finance and a MBA with a concentration in Accounting in 2004 and is a Certified Public Accountant in the State of New York. 

Ms. Turso is a Senior Accountant of Pharmakon, having joined in 2023. Prior to joining Pharmakon, she was a staff level auditor at WithumSmith+Brown in their Financial Services practice. During her time at Withum, Ms. Turso performed audits on private equity and hedge fund clients within the financial services and healthcare sectors. Ms. Turso graduated from the University of Scranton with a dual B.A. in Accounting and Marketing.

Ms. Colombo is an Executive Assistant at Pharmakon, having joined in 2022. She has over 20 years of experience in the Investment Banking and Finance Industry. Ms. Colombo previously worked at Credit Suisse and Merrill Lynch where she supported senior managers within COO, CFO and Finance. Ms. Colombo earned a B.A. in Sociology from (CSI) CUNY.